Details for New Drug Application (NDA): 202211

✉ Email this page to a colleague

NDA 202211 describes OXYTROL FOR WOMEN, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. Additional details are available on the OXYTROL FOR WOMEN profile page.

The generic ingredient in OXYTROL FOR WOMEN is oxybutynin. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxybutynin profile page.

Summary for 202211

Tradename:	OXYTROL FOR WOMEN
Applicant:	Abbvie
Ingredient:	oxybutynin
Patents:	0

Pharmacology for NDA: 202211

Mechanism of Action	Cholinergic Muscarinic Antagonists

Suppliers and Packaging for NDA: 202211

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211	NDA	Allergan, Inc.	0023-9637	0023-9637-04	16 PATCH in 1 CARTON (0023-9637-04) / 4 d in 1 PATCH
OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211	NDA	Allergan, Inc.	0023-9637	0023-9637-08	32 PATCH in 1 CARTON (0023-9637-08) / 4 d in 1 PATCH

Profile for product number 001

Active Rx/OTC/Discontinued:	OTC	Dosage:	FILM, EXTENDED RELEASE;TRANSDERMAL			Strength	3.9MG/24HR
Approval Date:	Jan 25, 2013	TE:		RLD:	Yes

Expired US Patents for NDA 202211

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211-001	Jan 25, 2013	⤷ Subscribe	⤷ Subscribe
Abbvie	OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211-001	Jan 25, 2013	⤷ Subscribe	⤷ Subscribe
Abbvie	OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211-001	Jan 25, 2013	⤷ Subscribe	⤷ Subscribe
Abbvie	OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211-001	Jan 25, 2013	⤷ Subscribe	⤷ Subscribe
Abbvie	OXYTROL FOR WOMEN	oxybutynin	FILM, EXTENDED RELEASE;TRANSDERMAL	202211-001	Jan 25, 2013	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.